九強生物(300406.SZ)取得3項專利證書
格隆匯 2 月 1日丨九強生物(300406.SZ)公佈,公司於近期收到中華人民共和國國家知識產權局頒發的3項專利證書,涉大腸桿菌β半乳糖苷酶受體的用途、S-腺苷甲硫氨酸合成酶製劑、及其製備方法和用途、一種苯巴比妥衍生物及其在免疫檢測中的用途。
上述發明專利證書的取得不會對公司近期生產經營產生重大影響,但在一定程度上有利於發揮公司的知識產權優勢,促進技術創新,有利於提升公司的核心競爭力,有利於公司形成持續創新機制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.